In Depth Research on Global Breast Cancer Vaccine Market and Clinical Pipeline Outlook 2022

“Global Breast Cancer Vaccine Market and Clinical Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global breast cancer vaccine development market. Currently there is no single breast cancer vaccine commercially available in the market. This report analyzes the ongoing clinical trial of 36 breast cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the vaccine. Most of the breast cancer vaccines in clinical trials are in preclinical phase followed by Phase-I trials. The advance stage of development of breast cancer vaccine in clinical trials across the globe is in Phase-III.

The conventional cancer treatment methods have proved their importance in last decade. They are widely accepted among patients and physicians (oncologists) because of familiarity and large amount of statistically significant data supporting their efficacy. Despite their benefits, they sometimes fall short in meeting the patient’s personal requirements. For instance, efficacy is a major requirement, but different patients display different response to the same medication, this is attributed to their unique genetic makeup. To meet the individual’s necessities, high efficacy and safety, concept of cancer vaccine was formulated.

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-global-breast-cancer-vaccine-market-and-clinical-pipeline-outlook-2022.php

Table of contents

What are Cancer Vaccines?

Mechanism of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

Mechanism of Breast Cancer Vaccine
3.1 Principle Strategies for Eliciting Immune System
3.1.1 Overcoming Immune Suppression
3.1.2 Modulation of Immune Checkpoints
3.2 Immunogenicity and Responses to Therapies
3.3 Breast Cancer Therapeutic Vaccines

Global Breast Cancer Incidence
4.1 US
4.2 Europe
4.3 Asia
4.4 Rest of the World

Global Breast Cancer Vaccine Market Current Scenario
5.1 Unexplored Opportunity
5.2 Global Breast Cancer Vaccine Pipeline Overview

Need for Personalized Breast Cancer Vaccines

Global Breast Cancer Vaccine Market Dynamics
7.1 Favorable Parameters
7.2 Commercialization Challenges

Global Breast Cancer Vaccine Market Future Prospects

FDA Guideline for the Development and Marketing of Cancer Vaccines
9.1 Considerations for Both Early and Late Phase Clinical Trials
9.1.1 Patient Population
9.1.2 Monitoring The Immune Response
9.1.3 Biomarkers As Evidence Of Efficacy
9.1.4 Adjuvants Used To Stimulate Immune Response
9.1.5 Multi-Antigen Vaccines
9.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
9.1.7 Concomitant And Subsequent Therapies
9.2 Considerations for Early Phase Clinical Trials
9.2.1 Starting Dose And Dosing Schedule
9.2.2 Booster And Maintenance Therapy
9.2.3 Dose Escalation
9.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development
9.3 Considerations For Late Phase Clinical Trials
9.3.1 Safety Profile From Early Phase Clinical Trials
9.3.2 Endpoints
9.3.3 Statistical Issues
9.3.4 Control Issues
9.3.5 Delayed Vaccine Effect
9.3.6 Autologous Vaccine Trials
9.3.7 Accelerated Approval Regulations

Global Breast Cancer Vaccine Clinical Pipeline by Company and Phase
10.1 Preclinical
10.2 Phase-I
10.3 Phase-I/II
10.4 Phase-II
10.5 Phase-II/III
10.6 Phase-III

Discontinued and Suspended Breast Cancer Vaccine in Clinical Pipeline by Company and Phase
11.1 Suspended
11.2 No Development Reported
11.3 Discontinued

Competitive Landscape
12.1 Advaxis
12.2 AlphaVax
12.3 AVAX Technologies
12.4 Dendreon Corporation
12.5 Galena Biopharma
12.6 Generex Biotechnology
12.7 GlaxoSmithKline
12.8 Immune Design
12.9 Imugene
12.10 Immunovative Therapies
12.11 Immunovaccine
12.12 Inovio Pharmaceuticals
12.13 Merck
12.14 NewLink Genetics
12.15 Recombio
12.16 TapImmune
12.17 ViroMed

Figure 1-1: Categorization and Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Development of a Cellular Immune Response against TAA
Figure 4-1: US andndash;Number of New Cases and Deaths of Breast Cancer, 2016
Figure 5-1: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
Figure 5-2: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
Figure 5-3: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
Figure 5-4: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
Figure 6-1: Overview of Personalized Cancer Vaccines Development
Figure 6-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 6-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Figure 7-1: Favorable Parameters for Breast Cancer Vaccine Development
Figure 7-2: Challenges for Breast Cancer Vaccine Market
Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: AlphaVax Clinical Pipeline Overview
Figure 12-3: Galena Biopharma Clinical Pipeline Overview
Figure 12-4: Generex Biotechnology Clinical Pipeline Overview
Figure 12-5: Immune Design Clinical Pipeline Overview
Figure 12-6: Imugene Clinical Pipeline Overview
Figure 12-7: Immunovaccine Clinical Pipeline Overview
Figure 12-8: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-9: NewLink Genetics Corporation Clinical Pipeline
Figure 12-10: TapImmune Clinical Pipeline Overview
Figure 12-11: ViroMed Clinical Pipeline Overview

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.